HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gorson, K. C. Articles by Ropper, A. H. Search for Related Content PubMed PubMed Citation Articles by Gorson, K. C. Articles by Ropper, A. H. Related Collections Chronic inflammatory demyelinating polyneuropathy All Clinical trials Clinical trials Observational study (Cohort, Case control) Related Article

Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy

From the Division of Neurology (Drs. Gorson and Ropper), St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA; and Department of Neurology (Dr. Amato), Brigham and Women’s Hospital, Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. Kenneth C. Gorson, Division of Neurology, St. Elizabeth’s Medical Center, 736 Cambridge Street, Boston, MA 02135; e-mail: kengorson{at}comcast.net

The authors retrospectively reviewed the efficacy of mycophenolate mofetil (MMF; mean dose, 2 g/day given for an average of 14 months) in 21 patients with immune demyelinating polyneuropathy. There were no significant differences in the median strength, sensory, or Rankin scores before and after treatment. In patients with immunoglobulin (Ig) M neuropathy, the M-protein decreased by 22%. Three patients with chronic inflammatory demyelinating polyneuropathy (30%) and one patient with IgM neuropathy (13%) improved. The authors found that MMF induced a modest benefit in ~20% of their patients and stabilized patient condition, allowing reduction of steroid or IVIg therapy.

Received February 11, 2004. Accepted in final form April 14, 2004.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the August 24 issue to find the link for this article.

Related Article

August 24 Highlights
Neurology 2004 63: 604-605. [Full Text] [PDF]

This article has been cited by other articles:

				H. C. Lehmann, G. Meyer zu Horste, B. C. Kieseier, and H.-P. Hartung Review: Pathogenesis and treatment of immune-mediated neuropathies Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 261 - 281. [Abstract] [PDF]

				M. R. Pranzatelli, E. D. Tate, A. L. Travelstead, C. A. Baumgardner, N. V. Gowda, S. N. Halthore, P. Kerstan, B. D. Kossak, W. G. Mitchell, and J. W. Taub Insights on Chronic-Relapsing Opsoclonus-Myoclonus From a Pilot Study of Mycophenolate Mofetil J Child Neurol, March 1, 2009; 24(3): 316 - 322. [Abstract] [PDF]

				M P J Garssen, R van Koningsveld, and P A van Doorn Treatment of Guillain Barre syndrome with mycophenolate mofetil: a pilot study J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 1012 - 1013. [Full Text] [PDF]

				J. R Overell and H. J Willison Chronic inflammatory demyelinating polyradiculoneuropathy: classification and treatment options Practical Neurology, April 1, 2006; 6(2): 102 - 110. [Full Text] [PDF]

				H. Koller, B. C. Kieseier, S. Jander, and H.-P. Hartung Chronic Inflammatory Demyelinating Polyneuropathy N. Engl. J. Med., March 31, 2005; 352(13): 1343 - 1356. [Full Text] [PDF]

				P Vermersch, T Stojkovic, and J de Seze Mycophenolate mofetil and neurological diseases Lupus, March 1, 2005; 14(3_suppl): s42 - s45. [Abstract] [PDF]

				P. Vermersch, T. Stojkovic, and J. de Seze Mycophenolate mofetil and neurological diseases Lupus, January 1, 2005; 14(1_suppl): s42 - s45. [Abstract] [PDF]